Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

to assess safety and immunogenicity of measles-rubella (MR) routine immunization in Indonesian Children and Infants

• to asses serious immediate systemic events,
• to assess local and systemic reaction after Measles-Rubella (MR) vaccine in infants and children,
• to evaluate protectivity and antibody response to measles and rubella after 1 dose of MR vaccine

Inclusion Criteria:

• Healthy infants (9-12 months) or children (18-47 months)
• Will receive MR routine immunization.
• Parents have been informed properly regarding the study and signed the informed consent form.
• Parents will commit themselves to comply with the instructions of the investigator and the schedule of the trial.

Exclusion Criteria:

• MR vaccine given simultaneously with other vaccination, except Pentabio (DTP/HB/Hib)